Showing 1641-1650 of 9336 results for "".
- Can the Sunshine Vitamin Lower Melanoma Risk?https://practicaldermatology.com/news/can-the-sunshine-vitamin-lower-melanoma-risk/2461490/Folks who regularly take vitamin D supplements may be less likely to develop melanoma than their counterparts who don’t tale these supplements, a new study finds. In addition, people taking vitamin D supplements regularly also had a considerably lower risk of skin cancer. The study, conducted in…
- Topline Results: Union's Oral Orismilast Improves PASI by Week 16 in Patients with Moderate to Severe PsOhttps://practicaldermatology.com/news/topline-results-unions-oral-orismilast-improves-pasi-by-week-16-in-patients-with-moderate-to-severe-pso/2461489/Oral orismilast performed well in adult patients with moderate to severe psoriasis, according to topline results from the IASOS Phase 2b study. Data from the 202 patients randomized and dosed in the study showed that all active arms of oral orismilast achieved the primary endpoint of percentage ch…
- Regenerative Medicine in Action: Scars Faded Using Transplanted Hair Follicleshttps://practicaldermatology.com/news/regenerative-medicine-in-action-scars-faded-using-transplanted-hair-follicles/2461486/Skin scars began to behave more like uninjured skin after they were treated with hair follicle transplants in a small new study. The scarred skin harboured new cells and blood vessels, remodelled collagen to restore healthy patterns, and even expressed genes found in healthy unscarred skin. “Af…
- Crown Taps Shellie Hammock as EVP and General Counselhttps://practicaldermatology.com/news/crown-taps-shellie-hammock-as-evp-and-general-counsel/2461483/Shellie Hammock is Crown Laboratory’s new Executive Vice President and General Counsel and will hold a position on the Executive Leadership Team and Global Strategic Planning Team. This is a new position within Crown that will provide strategic legal oversight across all aspects of the global org…
- Current Depression, Systemic Inflammation Linked in Psoriasishttps://practicaldermatology.com/news/current-depression-systemic-inflammation-linked-in-psoriasis/2461482/Current depression travels with increased neutrophils in psoriasis patients, especially females, finds research in the Journal of Investigative Dermatology. For the study, researchers used data from the U.K. Biobank to look at correlations between current and lifetime depression with neutrophil c…
- Journey Medical Corporation Shares Positive Comparative Pharmacokinetic Data for DFD-29 for Rosaceahttps://practicaldermatology.com/news/journey-medical-corporation-shares-positive-comparative-pharmacokinetic-data-for-dfd-29-for-rosacea/2461473/Journey Medical Corporation shared positive PK comparability data of DFD-29 and key updates on the progress of its pivotal Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. The PK study was designed as a single-center, …
- Sirnaomics' STP705 Shows Promise in Adults with Cutaneous Squamous Cell Carcinoma In Situhttps://practicaldermatology.com/news/sirnaomics-stp705-shows-promise-in-adults-with-cutaneous-squamous-cell-carcinoma-in-situ/2461469/Sirnaomics' STP705 shows promise for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC), according to interim results of part-one of an ongoing Phase IIb clinical trial. The majority (78%) of 32 patients with STP705 treatment achieved histological clearance, and one of the three t…
- Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancerhttps://practicaldermatology.com/news/immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer/2461468/Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System Immunomic Therapeutics received FDA fast track designation for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer. …
- Rocatinlimab Shows Promise in ADhttps://practicaldermatology.com/news/rocatinlimab-shows-promise-in-ad/2461465/Rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results in atopic dermatitis patients both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet. Rocatinlimab inhibits OX40—an immune molecule invol…
- UCB's Bimekizumab Performs Well in Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-hidradenitis-suppurativa/2461464/UCB’s bimekizumab may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa, according to topline results from two Phase 3 studies, BE HEARD I and BE HEARD II. The positive results from these two studies will form the basis of global regulatory license applic…